NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

Impact · against what's priced in

NNVC creates a potential high-value liquidity event via a Priority Review Voucher application for its measles candidate, which could provide non-dilutive funding far exceeding its small-cap valuation. ZPHR improves its capital position for the Paradox Project through a $15 million letter of intent.

NNVC+0.70: No priced-in read yet

NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

What matters in this story

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

What matters in this story

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

How each ticker is affected

Track these names every morning.

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial

CSL strikes US$1.6 billion licensing deal for rare disease drug

Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway

NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

What matters in this story

Next reads from the same story arc

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI

What matters in this story

Next reads from the same story arc

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

How each ticker is affected

Track these names every morning.

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Inside Biotech: Aroa Biosurgery's Symphony improves diabetic foot ulcer healing in US clinical trial

CSL strikes US$1.6 billion licensing deal for rare disease drug

Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway